Motixafortide and Natalizumab to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease (SCD)
Condition: Sickle Cell Disease Interventions: Drug: Motixafortide; Drug: Natalizumab; Procedure: Leukapheresis Sponsors: Washington University School of Medicine; BioLineRx, Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Gene Therapy | Genetics | Research | Sickle Cell Anemia | Stem Cell Therapy | Stem Cells | Tysabri